<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Roche Holding Ltd — News on 6ix</title>
<link>https://6ix.com/company/roche-holding-ltd</link>
<description>Latest news and press releases for Roche Holding Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/roche-holding-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69da15b8d20c3ebdd611babe.webp</url>
<title>Roche Holding Ltd</title>
<link>https://6ix.com/company/roche-holding-ltd</link>
</image>
<item>
<title>[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc</title>
<link>https://6ix.com/company/roche-holding-ltd/news/ad-hoc-announcement-pursuant-to-art-53-lr-roche-reports-strong-sales-growth-of-6percent-at-constant-exchange-rates-in-the-first-quarter-of-2026-5percent-in-chf-due-to-the-significant-appreciation-of-the-swiss-franc</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/ad-hoc-announcement-pursuant-to-art-53-lr-roche-reports-strong-sales-growth-of-6percent-at-constant-exchange-rates-in-the-first-quarter-of-2026-5percent-in-chf-due-to-the-significant-appreciation-of-the-swiss-franc</guid>
<pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
<description>Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics.Pharmaceuticals Division sales were +7% at CER, -4% when reported in CHF and +10% in USD, due to continued high growth in sales of medicines for the treatment of severe diseases; Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases) and Ocrev</description>
</item>
<item>
<title>Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roches-fenebrutinib-significantly-reduced-relapses-versus-standard-of-care-to-approximately-one-every-17-years-in-rms</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roches-fenebrutinib-significantly-reduced-relapses-versus-standard-of-care-to-approximately-one-every-17-years-in-rms</guid>
<pubDate>Tue, 21 Apr 2026 23:15:00 GMT</pubDate>
<description>Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS)Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomideFenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral for both RMS and primary progressive multiple sclerosis (PPMS)The totality of R</description>
</item>
<item>
<title>Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roches-enspryng-satralizumab-reduces-risk-of-relapses-by-68percent-demonstrating-potential-to-become-first-treatment-for-mogad</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roches-enspryng-satralizumab-reduces-risk-of-relapses-by-68percent-demonstrating-potential-to-become-first-treatment-for-mogad</guid>
<pubDate>Tue, 21 Apr 2026 15:45:00 GMT</pubDate>
<description>Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe and debilitatingData will be submitted to regulatory authorities Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrat</description>
</item>
<item>
<title>FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus</title>
<link>https://6ix.com/company/roche-holding-ltd/news/fda-accepts-application-for-roches-gazyvagazyvaro-for-the-treatment-of-the-most-common-form-of-lupus</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/fda-accepts-application-for-roches-gazyvagazyvaro-for-the-treatment-of-the-most-common-form-of-lupus</guid>
<pubDate>Tue, 21 Apr 2026 05:00:00 GMT</pubDate>
<description>Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy to directly target B cells in SLE, potentially becoming the new standard of care for this condition1SLE is a potentially life-threatening autoimmune disease affecting more than three million people worldwide – achieving better disease contr</description>
</item>
<item>
<title>Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roche-receives-ce-mark-for-new-elecsys-nfl-blood-test-to-detect-neuroinflammation-in-multiple-sclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roche-receives-ce-mark-for-new-elecsys-nfl-blood-test-to-detect-neuroinflammation-in-multiple-sclerosis</guid>
<pubDate>Mon, 13 Apr 2026 05:00:00 GMT</pubDate>
<description>The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.1This minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods.By providing deeper insight into underlying neuroinflammatory activity, Elecsys NfL has the potential to enable effective MS monitoring and earlier clinical intervention. 2, 3 Basel, 13 April 2026 -</description>
</item>
<item>
<title>C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)</title>
<link>https://6ix.com/company/roche-holding-ltd/news/c4-therapeutics-expands-long-term-partnership-with-roche-through-new-collaboration-agreement-focused-on-discovering-and-developing-degrader-antibody-conjugates-dacs-1</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/c4-therapeutics-expands-long-term-partnership-with-roche-through-new-collaboration-agreement-focused-on-discovering-and-developing-degrader-antibody-conjugates-dacs-1</guid>
<pubDate>Thu, 09 Apr 2026 10:59:00 GMT</pubDate>
<description>Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to Receive $20 Million Upfront Payment and Eligible to Receive Over $1 Billion in Discovery, Development and Commercial Milestones, in Addition to Future Royalties WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopha</description>
</item>
<item>
<title>Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roche-launches-the-cobas-mpx-e-assay-a-new-4-in-1-donor-screening-test-to-further-safeguard-the-global-blood-supply</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roche-launches-the-cobas-mpx-e-assay-a-new-4-in-1-donor-screening-test-to-further-safeguard-the-global-blood-supply</guid>
<pubDate>Mon, 30 Mar 2026 05:00:00 GMT</pubDate>
<description>The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs.The new test delivers faster turnaround times and allows labs to implement Hepatitis E (HEV) screening without requiring additional instrumentation.This assay is designed for use on the fully automated cobas x800 systems, enabling high-throughput screening with up to 8 hours of walk-away time. Basel, 30 March 2026 - Roche (SIX: RO, RO</description>
</item>
<item>
<title>/C O R R E C T I O N -- Roche/</title>
<link>https://6ix.com/company/roche-holding-ltd/news/c-o-r-r-e-c-t-i-o-n-roche-1</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/c-o-r-r-e-c-t-i-o-n-roche-1</guid>
<pubDate>Tue, 24 Mar 2026 19:27:00 GMT</pubDate>
<description>Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test designed to detect a broad spectrum of viruses and bacteria that cause respiratory illness. The test is now available in countries accepting the CE mark.</description>
</item>
<item>
<title>Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roche-inaugurates-new-research-home-for-the-institute-of-human-biology-pioneering-human-model-systems-to-accelerate-drug-discovery-and-development</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roche-inaugurates-new-research-home-for-the-institute-of-human-biology-pioneering-human-model-systems-to-accelerate-drug-discovery-and-development</guid>
<pubDate>Mon, 23 Mar 2026 15:00:00 GMT</pubDate>
<description>The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Switzerland and the Basel life sciences clusterThe Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patientsFederal Councillor Elisabeth Baume-Schneider, Head of the Federal Department of Home Affairs (FDHA), will attend the official opening ceremony Basel, 23 March 2026 - Roche (SIX: RO, ROP; OTC</description>
</item>
<item>
<title>Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roche-expands-mass-spectrometry-menu-to-include-steroid-assays-receiving-clia-moderate-complexity-designation-1</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roche-expands-mass-spectrometry-menu-to-include-steroid-assays-receiving-clia-moderate-complexity-designation-1</guid>
<pubDate>Wed, 18 Mar 2026 13:00:00 GMT</pubDate>
<description>Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has categorized its Ionify® steroid assays for mass spectrometry as "moderate complexity" under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). This designation marks an important step toward expanding access to advanced diagnostic testing, which has historically been limited to highly specialized laboratories due to complex workflows and the need for expert operators.The Ionify® st</description>
</item>
<item>
<title>Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roche-launches-nvidia-ai-factory-to-accelerate-the-development-of-new-therapeutics-and-diagnostics-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roche-launches-nvidia-ai-factory-to-accelerate-the-development-of-new-therapeutics-and-diagnostics-solutions</guid>
<pubDate>Mon, 16 Mar 2026 20:30:00 GMT</pubDate>
<description>With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs. The new computational infrastructure supports Roche’s vision of building an AI-accelerated healthcare organisation.NVIDIA AI factories help accelerate discoveries, enable more efficient clinical trials, and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes. Basel, 16 March 2026 -</description>
</item>
<item>
<title>AI in Life Sciences Market, 2026-2040 Industry Trends and Global Forecasts - IBM, IQVIA and Oracle Lead Data Platforms While Roche, Pfizer and AI Startups Accelerate Drug Discovery Innovation</title>
<link>https://6ix.com/company/roche-holding-ltd/news/ai-in-life-sciences-market-2026-2040-industry-trends-and-global-forecasts-ibm-iqvia-and-oracle-lead-data-platforms-while-roche-pfizer-and-ai-startups-accelerate-drug-discovery-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/ai-in-life-sciences-market-2026-2040-industry-trends-and-global-forecasts-ibm-iqvia-and-oracle-lead-data-platforms-while-roche-pfizer-and-ai-startups-accelerate-drug-discovery-innovation</guid>
<pubDate>Fri, 13 Mar 2026 09:35:00 GMT</pubDate>
<description>AI in life sciences presents key opportunities in drug discovery, personalized medicine, and diagnostics by leveraging vast datasets for precise, cost-effective solutions. Growth is driven by increased data, demand for precision therapies, and partnerships with tech leaders, despite challenges in costs and regulation. AI in Life Sciences Market AI in Life Sciences Market Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "AI in Life Sciences Market, till 2040: Distribution by Deployment Mode, Type o</description>
</item>
<item>
<title>Roche Annual General Meeting 2026</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roche-annual-general-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roche-annual-general-meeting-2026</guid>
<pubDate>Tue, 10 Mar 2026 13:15:00 GMT</pubDate>
<description>Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed39th consecutive dividend increase to CHF 9.80 per shareExchange of non-voting equity securities (Genussscheine) for Participation Certificates approved Basel, 10 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its Annual G</description>
</item>
<item>
<title>Pegasys (Roche, pharmaand) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/roche-holding-ltd/news/pegasys-roche-pharmaand-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/pegasys-roche-pharmaand-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Tue, 10 Mar 2026 09:51:00 GMT</pubDate>
<description>Key opportunities for the Pegasys market include personalized treatment approaches, expansion into emerging markets, focus on long-acting therapies, increased use in oncology and hematology, and localized manufacturing. Rising hepatitis B prevalence and healthcare spending further bolster growth.Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Pegasys Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering The Pegasys m</description>
</item>
<item>
<title>[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer</title>
<link>https://6ix.com/company/roche-holding-ltd/news/ad-hoc-announcement-pursuant-to-art-53-lr-roche-provides-update-on-phase-iii-persevera-study-in-er-positive-advanced-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/ad-hoc-announcement-pursuant-to-art-53-lr-roche-provides-update-on-phase-iii-persevera-study-in-er-positive-advanced-breast-cancer</guid>
<pubDate>Mon, 09 Mar 2026 06:00:00 GMT</pubDate>
<description>persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatmentRoche is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting1,2The FDA r</description>
</item>
<item>
<title>New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus</title>
<link>https://6ix.com/company/roche-holding-ltd/news/new-england-journal-of-medicine-publishes-phase-iii-allegory-data-showing-roches-gazyvagazyvaro-significantly-reduces-disease-activity-in-the-most-common-form-of-lupus-14</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/new-england-journal-of-medicine-publishes-phase-iii-allegory-data-showing-roches-gazyvagazyvaro-significantly-reduces-disease-activity-in-the-most-common-form-of-lupus-14</guid>
<pubDate>Fri, 06 Mar 2026 13:45:00 GMT</pubDate>
<description>Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)If approved, Gazyva/Gazyvaro would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity1SLE is a potentially life-threatening a</description>
</item>
<item>
<title>Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity</title>
<link>https://6ix.com/company/roche-holding-ltd/news/roche-announces-positive-phase-ii-results-for-petrelintide-an-amylin-analog-developed-for-people-living-with-overweight-and-obesity-12</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/roche-announces-positive-phase-ii-results-for-petrelintide-an-amylin-analog-developed-for-people-living-with-overweight-and-obesity-12</guid>
<pubDate>Thu, 05 Mar 2026 18:45:00 GMT</pubDate>
<description>Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerabilityAt the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse eventsThe data support further development of petrelintide in chronic weight management as monotherapy and its tolerability profile also confirms its value as a combination partner Basel, 05 March 2026 - Roche (</description>
</item>
<item>
<title>[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)</title>
<link>https://6ix.com/company/roche-holding-ltd/news/ad-hoc-announcement-pursuant-to-art-53-lr-roches-fenebrutinib-confirms-its-potential-as-first-and-only-btk-inhibitor-for-relapsing-and-primary-progressive-ms-in-third-positive-phase-iii-study-fenhance-1</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/ad-hoc-announcement-pursuant-to-art-53-lr-roches-fenebrutinib-confirms-its-potential-as-first-and-only-btk-inhibitor-for-relapsing-and-primary-progressive-ms-in-third-positive-phase-iii-study-fenhance-1</guid>
<pubDate>Mon, 02 Mar 2026 06:00:00 GMT</pubDate>
<description>FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reductionFENhance 1 is the final study readout of the fenebrutinib pivotal clinical development programme in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive multiple sclerosis (PPMS)Fenebrutinib has the potential to become the fir</description>
</item>
<item>
<title>FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer</title>
<link>https://6ix.com/company/roche-holding-ltd/news/fda-accepts-new-drug-application-for-roches-giredestrant-in-esr1-mutated-er-positive-advanced-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/fda-accepts-new-drug-application-for-roches-giredestrant-in-esr1-mutated-er-positive-advanced-breast-cancer</guid>
<pubDate>Fri, 20 Feb 2026 06:00:00 GMT</pubDate>
<description>Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard-of-care endocrine therapy plus everolimus1Strength of evERA data demonstrate potential for giredestrant combination to help address resistance to standard-of-care therapies, and could be the first and only oral SERD combination approved in the post-CDK4/6 inhibitor setting1The FDA has set</description>
</item>
<item>
<title>Change to the Roche Enlarged Corporate Executive Committee</title>
<link>https://6ix.com/company/roche-holding-ltd/news/change-to-the-roche-enlarged-corporate-executive-committee</link>
<guid isPermaLink="true">https://6ix.com/company/roche-holding-ltd/news/change-to-the-roche-enlarged-corporate-executive-committee</guid>
<pubDate>Tue, 17 Feb 2026 06:00:00 GMT</pubDate>
<description>Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. Based in Basel, he will also become a member of the Enlarged Corporate Executive Committee. Roche CEO Thomas Schinecker commented: "Mark Dawson is a distinguished physician-scientist with a profound dedication to scientific excellence and patient care. His collaborative spirit and tho</description>
</item>
</channel>
</rss>